Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
WGS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.56 - $117.75
Previous CloseN/A
Volume338.68K
Average Volume (3M)808.71K
Market Cap
$1.91B
Enterprise Value$2.13B
Total Cash (Recent Filing)$108.13M
Total Debt (Recent Filing)$45.02M
Price to Earnings (P/E)38.8
Beta1.56
Next Earnings
Aug 18, 2025EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding28,531,643
10 Day Avg. Volume900,481
30 Day Avg. Volume808,709
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.95
Enterprise Value/Ebitda-70.81
Forecast
1Y Price Target
$102.00Price Target Upside52.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe expansion into the NICU market is seen as a new growth driver, with the potential for significant revenue from an estimated 200,000 tests opportunity.
ProfitabilityGeneDx delivered on its goal of GAAP profitability, ahead of expectations, with an adjusted net income of $17M in the fourth quarter.
Revenue GrowthWGS exited on a high note, with material upside to 4Q revenues and EBITDA.
Bears Say
Conservative GuidanceThe new guidance looks conservative on many fronts, supporting the Buy rating and increased price target.
Legal ConcernsA short report alleges wholesale reimbursement fraud at GeneDx, which led to a decrease in the company's shares.
Market PerceptionDespite strong performance, shares faced pressure due to allegations of fraud, impacting investor sentiment.
---
Ownership Overview
61.07% Insiders
4.80% Mutual Funds
0.53% Other Institutional Investors
26.67% Public Companies and
Individual Investors
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $18.56 and its highest was $117.75 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $1.91B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Aug 18, 2025 which is in 109 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Apr 30, 2025. The company reported $0.275 earnings per share for the quarter, beating the consensus estimate of $0.059 by $0.216.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Undervalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.12.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 28,531,643 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.275 in its last earnings report, beating expectations of $0.059. Following the earnings report the stock price went down -42.849%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
---
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$102.00 (52.58% Upside)
$102.00 (52.58% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 444.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.62%
12-Months-Change
Fundamentals
Return on Equity
-22.10%
Trailing 12-Months
Asset Growth
-1.89%
Trailing 12-Months
Company Description
GeneDx Holdings
GeneDx Holdings (WGS) is a company operating in the biotechnology sector, specializing in genomic diagnostics and precision medicine. The company focuses on providing genomic testing services that aid in the diagnosis and treatment of genetic disorders. GeneDx Holdings leverages advanced sequencing technologies and bioinformatics to offer a comprehensive range of genetic testing solutions, catering to healthcare providers, researchers, and patients. Its core services include exome and genome sequencing, as well as specific panels for hereditary conditions.
---
WGS Company Deck
---
WGS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, profitability, and strategic advancements like the Fabric Genomics acquisition. However, challenges such as weather impacts on volumes and increased G&A expenses were noted. The company's positive momentum and strategic initiatives outweigh these challenges.Read More>---
WGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
---
WGS Stock 12 Month Forecast
Average Price Target
$102.00
▲(52.58% Upside)
Technical Analysis
---